You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)公佈中期業績:總收入達2.615億元 虧損額大幅收窄
格隆匯 08-15 22:33

格隆匯8月15日丨基石藥業-B(02616.HK)公佈中期業績,於2023年上半年,基石藥業碩果累累,在日趨成熟的產品管線及業務經營方面達成多個里程碑。公司有四款已上市產品,持續創收穩定的收入,為進一步的增長計劃提供財力及資金。

截至2023年6月30日止六個月及截至公吿日期,公司的產品管線及業務經營均已取得重大進展。總收入達人民幣2.615億元,其中精準治療藥物銷售額為人民幣2.469億元,舒格利單抗特許權使用費收入為人民幣1460萬元。

期內虧損由截至2022年6月30日止六個月的人民幣3.616億元減少人民幣1.524億元或42%至截至2023年6月30日止六個月的人民幣2.092億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account